Akoya Biosciences (NASDAQ:AKYA – Get Rating) is one of 43 publicly-traded companies in the “Analytical instruments” industry, but how does it compare to its peers? We will compare Akoya Biosciences to related businesses based on the strength of its dividends, analyst recommendations, profitability, earnings, institutional ownership, risk and valuation.
Institutional & Insider Ownership
27.6% of Akoya Biosciences shares are held by institutional investors. Comparatively, 61.9% of shares of all “Analytical instruments” companies are held by institutional investors. 11.2% of shares of all “Analytical instruments” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Akoya Biosciences and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Akoya Biosciences||$54.92 million||-$42.94 million||-2.38|
|Akoya Biosciences Competitors||$1.19 billion||$356.47 million||-25.04|
Akoya Biosciences’ peers have higher revenue and earnings than Akoya Biosciences. Akoya Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares Akoya Biosciences and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Akoya Biosciences Competitors||-172.02%||3.96%||-9.45%|
This is a summary of current ratings and target prices for Akoya Biosciences and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Akoya Biosciences Competitors||308||1312||1821||57||2.47|
Akoya Biosciences presently has a consensus price target of $20.00, indicating a potential upside of 86.22%. As a group, “Analytical instruments” companies have a potential upside of 28.06%. Given Akoya Biosciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe Akoya Biosciences is more favorable than its peers.
Akoya Biosciences peers beat Akoya Biosciences on 7 of the 12 factors compared.
About Akoya Biosciences (Get Rating)
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. It offers single-cell resolution with spatial context that provides a wealth of information to visualize tissue organization and disease pathology on a molecular level to understand disease progression and treatment response. The company also provides PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen, or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. In addition, it offers Proxima, a cloud-based platform designed to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.